Ocular Therapeutix™ will participate in three upcoming investor conferences
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company specializing in the formulation, development and commercialization of innovative therapies for ocular diseases and conditions, today announced its attendance at the following conferences:
Jefferies London Healthcare Conference
Fireside Chat Date: Wednesday, November 16, 2022
Fireside chat time: 14:05 GMT
Location: Waldorf Hilton, London, UK
BTIG Virtual Ophthalmology Day 2022
Fireside Chat Date: Tuesday, November 29, 2022
Fireside Chat Time: 8:30 a.m. EST
Piper Sandler 34th Annual Health Care Conference
Fireside Chat Date: Wednesday, November 30, 2022
Fireside Chat Time: 12:00 p.m. EST
Location: Lotte New York Palace, New York, NY
Management will be available throughout the day for meetings with investors at all three conferences. If you plan to attend at least one of the conferences and would like to meet with management, please contact your Jefferies, BTIG or Piper Sandler representative.
A live webcast of fireside chats at the Jefferies London Healthcare Conference and Piper Sandler 34e The annual healthcare conference can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. It will also be available for replay for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the formulation, development and commercialization of innovative therapies for ocular diseases and conditions using its proprietary bioabsorbable hydrogel formulation technology. Ocular Therapeutix’s first commercial drug, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s early development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (intracanalicular cyclosporine insert) for the chronic treatment of dry eye disease and OTX-DED (intracanalicular dexamethasone insert) for the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials.